Mufemilast

莫米司特

Report date: 2026/05/11 20:01:57
NME

Base Information

Drug NameMufemilast
Drug Alias Name莫米欣Hemay-005
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInterleukin-1 receptor antagonistsTumor necrosis factor α inhibitorsPhosphodiesterase 4B inhibitors +[4] 
TargetsInterleukin-1 receptorTumor necrosis factor αPhosphodiesterase 4B +[4] 
Therapy Area/IndicationsPlaque psoriasisPsoriasisDermatitis, Atopic +[9] 
Global Approved IndicationsPlaque psoriasis
Approved Indications in ChinaPlaque psoriasis
Original Approved Country/TerritoryMainland China
Original Approved Date2025/09/30
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesTianjin Hemay Pharmaceutical Co LtdHainan Hailing Chemipharma Corporation Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesAnhui Hemay Pharmaceutical Co LtdTianjin Hemay Bio-Tech Co LtdGanzhou Hemei Pharmaceutical Co Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisPsoriasisDermatitis, Atopic +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A